RIMEPORIDE

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C11H15N3O5S2
Molecular Weight	333.384
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=CC(=C(C=C1C(=O)NC(N)=N)S(C)(=O)=O)S(C)(=O)=O

InChI

InChIKey=GROMEQPXDKRRIE-UHFFFAOYSA-N

InChI=1S/C11H15N3O5S2/c1-6-4-8(20(2,16)17)9(21(3,18)19)5-7(6)10(15)14-11(12)13/h4-5H,1-3H3,(H4,12,13,14,15)

HIDE SMILES / InChI

Molecular Formula	C11H15N3O5S2
Molecular Weight	333.384
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.treat-nmd.eu/resources/tact/reviews/past/rimeporide/ | https://www.ncbi.nlm.nih.gov/pubmed/26291649 | https://clinicaltrials.gov/ct2/show/results/NCT02710591 | https://www.nmd-journal.com/article/S0960-8966(16)30547-8/abstract

Rimeporide (EMD-87580) is an Na/H-exchanger-1 (NHE-1) inhibitor and was initially developed for heart failure. This compound reduces the development of both necrosis and hypertrophy, and it was shown to prevent early death in hereditary cardiomyopathy. Rimeporide regulates sodium, pH, calcium overload, reduces inflammation in several muscles, and decreases skeletal, diaphragm and cardiac fibrosis, and muscle cell degeneration. It was therefore further developed as a drug for treatment in Duchenne muscular dystrophy and other muscular dystrophies. Rimeporide is expected to act as a muscle-sparing agent. A phase I study has been completed in 2018.

Approval Year

PubMed

Title	Date	PubMed
Na+/H+ exchanger isoform 1 facilitates cardiomyocyte embryonic stem cell differentiation.	2009-01	19011045
[Effect of NHE1 on stem cell differentiation into cardiomyocytes].	2008-10	19149193
NHE-1 inhibition improves cardiac mitochondrial function through regulation of mitochondrial biogenesis during postinfarction remodeling.	2006-10	16679399
Antihypertrophic effect of Na+/H+ exchanger isoform 1 inhibition is mediated by reduced mitogen-activated protein kinase activation secondary to improved mitochondrial integrity and decreased generation of mitochondrial-derived reactive oxygen species.	2006-06	16513848
Influence of renal dysfunction on the pharmacokinetics of the selective Na+/H+ exchange inhibitor EMD 87 580 in patients with chronic heart failure.	2005-11	16300166
NHE-1-dependent intracellular sodium overload in hypertrophic hereditary cardiomyopathy: prevention by NHE-1 inhibitor.	2005-04	15808834
NHE-1 inhibition improves impaired mitochondrial permeability transition and respiratory function during postinfarction remodelling in the rat.	2005-01	15623430
Inhibitors of the Na+/H+ exchanger cannot prevent atrial electrical remodeling in the goat.	2004-04	15089994
Inhibition and reversal of myocardial infarction-induced hypertrophy and heart failure by NHE-1 inhibition.	2004-01	14684366
Optimal dose and mode of delivery of Na+/H+ exchange-1 inhibitor are critical for reducing postsurgical ischemia-reperfusion injury.	2003-11	14602297

Patents

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:33:45 GMT 2025` Edited by `admin` on `Mon Mar 31 18:33:45 GMT 2025`
Record UNII	QH6B4V5743
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

rimeporide [INN]

Preferred Name

English

RIMEPORIDE

Official Name

English

N-(AMINOIMINOMETHYL)-4,5-BIS(METHANESULFONYL)-2-METHYLBENZAMIDE

Systematic Name

English

Classification Tree Code System Code

EU-Orphan Drug

EU/3/15/1478